In today’s session Kite Pharma Inc (KITE) recorded an unusually high (613) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious KITE decrease. With 613 contracts traded and 4834 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: KITE161118P00045000 closed last at: $0.65 or 66.7% down. About 240,888 shares traded hands. Kite Pharma Inc (NASDAQ:KITE) has risen 2.48% since April 11, 2016 and is uptrending. It has underperformed by 3.67% the S&P500.
Kite Pharma Inc (NASDAQ:KITE) Ratings Coverage
Out of 9 analysts covering Kite Pharma (NASDAQ:KITE), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. $100 is the highest target while $58 is the lowest. The $83.07 average target is 62.75% above today’s ($51.04) stock price. Kite Pharma has been the topic of 22 analyst reports since August 4, 2015 according to StockzIntelligence Inc. FBR Capital upgraded the shares of KITE in a report on Tuesday, January 19 to “Outperform” rating. The rating was upgraded by Standpoint Research to “Buy” on Tuesday, December 15. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Equal-Weight” rating given on Wednesday, July 6 by Barclays Capital. Suntrust Robinson initiated Kite Pharma Inc (NASDAQ:KITE) on Friday, January 29 with “Buy” rating. The company was initiated on Thursday, September 3 by FBR Capital. The firm has “Equal-Weight” rating given on Tuesday, August 9 by Barclays Capital. Raymond James initiated the shares of KITE in a report on Thursday, June 2 with “Outperform” rating. Standpoint Research initiated Kite Pharma Inc (NASDAQ:KITE) rating on Tuesday, August 18. Standpoint Research has “Buy” rating and $100 price target. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Buy” rating given on Friday, August 14 by Guggenheim. The rating was maintained by FBR Capital on Tuesday, December 8 with “Mkt Perform”.
According to Zacks Investment Research, “Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.”
Insitutional Activity: The institutional sentiment increased to 1.57 in 2016 Q2. Its up 0.38, from 1.19 in 2016Q1. The ratio is positive, as 23 funds sold all Kite Pharma Inc shares owned while 37 reduced positions. 23 funds bought stakes while 71 increased positions. They now own 36.34 million shares or 0.96% less from 36.69 million shares in 2016Q1.
Vanguard Gru Incorporated accumulated 2.94M shares or 0.01% of the stock. Rtw Investments Ltd Liability Corp has 285,518 shares for 4.88% of their US portfolio. Sphera Funds Mgmt holds 0.65% or 50,000 shares in its portfolio. Moreover, Shikiar Asset Management Inc has 0.88% invested in Kite Pharma Inc (NASDAQ:KITE) for 39,500 shares. Cap World has 0.02% invested in the company for 1.52 million shares. Royal National Bank & Trust Of Canada accumulated 167,206 shares or 0.01% of the stock. Blackrock Japan Limited has invested 0% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Rock Springs Cap Mgmt L P last reported 0.3% of its portfolio in the stock. Qs Limited Company last reported 0% of its portfolio in the stock. Dsam Partners (London) Limited holds 3.53% or 231,385 shares in its portfolio. Amer Century Companies Incorporated reported 300,160 shares or 0.02% of all its holdings. Rice Hall James And Llc owns 41,001 shares or 0.12% of their US portfolio. Blackrock Institutional Tru Na has 0.01% invested in the company for 1.02M shares. Ladenburg Thalmann Financial has invested 0% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Dai Ichi Life Ins Limited has 22,058 shares for 0.03% of their US portfolio.
Insider Transactions: Since May 31, 2016, the stock had 0 insider purchases, and 9 sales for $2.93 million net activity. 10,000 shares were sold by BUTITTA CYNTHIA M, worth $582,775. 1,500 shares with value of $75,007 were sold by Wiezorek Jeffrey on Friday, July 1. On Monday, June 6 DOUMANI ROY sold $812,581 worth of the stock or 14,000 shares.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $2.60 billion. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. It currently has negative earnings. The Firm offers engineered autologous cell therapy , which is an approach to the treatment of cancer.
KITE Company Profile
Kite Pharma, Inc., incorporated on June 1, 2009, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Firm offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T cells are designed to recognize and destroy cancer cells. The Firm is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR therapy.
More notable recent Kite Pharma Inc (NASDAQ:KITE) news were published by: Seekingalpha.com which released: “Kite Pharma: So Much Promise, So Many Questions” on November 07, 2016, also Businesswire.com with their article: “Kite Pharma to Report Third Quarter 2016 Financial Results on November 9, 2016” published on November 02, 2016, Forbes.com published: “Kite Pharma Enters Oversold Territory (KITE)” on October 19, 2016. More interesting news about Kite Pharma Inc (NASDAQ:KITE) were released by: Finance.Yahoo.com and their article: “Kite Pharma Reports Third Quarter 2016 Financial Results” published on November 09, 2016 as well as Zacks.com‘s news article titled: “Will Kite Pharma (KITE) Stock Surprise Post Q3 Earnings?” with publication date: November 04, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.